{"hands_on_practices": [{"introduction": "The transition from preclinical research to first-in-human (FIH) trials represents a pivotal moment in drug development, requiring a careful synthesis of all available data to select a safe and informative starting dose. This exercise ([@problem_id:4598103]) simulates this critical step by having you apply steady-state pharmacokinetic principles to calculate an oral dosing regimen based on a target concentration. You will gain hands-on experience in projecting a clinical dose and confronting the real-world challenge of uncertainty in key parameters like bioavailability.", "problem": "A new extended-release oral small-molecule is transitioning from preclinical studies to first-in-human (FIH) evaluation. Physiologically based pharmacokinetic (PBPK) modeling predicts a human systemic clearance (CL) of $7.2$ L/h. A once-every-$12$-hour dosing interval, denoted by $\\tau = 12$ h, is planned. The formulation has sustained input designed to minimize peak-to-trough fluctuation; the predicted terminal half-life is $t_{1/2} = 18$ h, which is longer than the dosing interval ($t_{1/2} > \\tau$), so the steady-state trough concentration is expected to be close to the steady-state average concentration, with deviation under approximately $10\\%$. The minimum efficacious concentration (MEC) inferred from pharmacodynamic models is $1.1$ mg/L, and the clinical team wishes to target a steady-state trough of $1.1$ mg/L to ensure the concentration does not fall below the MEC. The nominal oral bioavailability (F) expected for the extended-release capsule is $0.42$, based on preclinical dog studies, but there is uncertainty: a plausible range is $0.30$ to $0.60$ due to potential formulation and interspecies differences.\n\nUsing first principles of steady-state mass balance for linear pharmacokinetics, compute the single dose administered every $\\tau$ hours that achieves a steady-state trough concentration of $1.1$ mg/L under the approximation $C_{\\text{ss,trough}} \\approx C_{\\text{ss,avg}}$. Express your final answer in mg and round your answer to four significant figures.\n\nThen, in your reasoning, discuss the sensitivity of the required dose to uncertainty in oral bioavailability (F) in FIH planning and quantify the fractional change in the required dose if the true $F$ is $0.30$ instead of $0.42$. Your final numerical answer should be only the computed dose per dosing interval.", "solution": "The problem is valid as it is scientifically grounded in the principles of clinical pharmacokinetics, is well-posed with sufficient and consistent data, and is expressed objectively.\n\nThe fundamental principle for determining a maintenance dosing regimen for a drug exhibiting linear pharmacokinetics is the concept of mass balance at steady state. At steady state ($ss$), the rate at which the drug is administered and absorbed into the systemic circulation must equal the rate at which it is eliminated from the body.\n\nThe average rate of drug administration into the systemic circulation (Rate In) for an oral drug with dose $D$, dosing interval $\\tau$, and oral bioavailability $F$ is given by:\n$$ \\text{Rate In} = \\frac{F \\times D}{\\tau} $$\nThe average rate of drug elimination from the body (Rate Out) is the product of the systemic clearance ($CL$) and the average steady-state plasma concentration ($C_{\\text{ss,avg}}$):\n$$ \\text{Rate Out} = CL \\times C_{\\text{ss,avg}} $$\nAt steady state, we equate these two rates:\n$$ \\frac{F \\times D}{\\tau} = CL \\times C_{\\text{ss,avg}} $$\nThe problem asks to calculate the dose $D$ required to achieve a target steady-state trough concentration ($C_{\\text{ss,trough}}$) of $1.1$ mg/L. A crucial piece of information is that the drug's predicted terminal half-life ($t_{1/2} = 18$ h) is longer than the dosing interval ($\\tau = 12$ h). For an extended-release formulation under such conditions ($t_{1/2} > \\tau$), the fluctuation between peak and trough concentrations at steady state is minimal. The problem statement formalizes this by providing the approximation that the trough concentration is nearly equal to the average concentration:\n$$ C_{\\text{ss,trough}} \\approx C_{\\text{ss,avg}} $$\nTherefore, we can set our target average steady-state concentration to be the target trough concentration:\n$$ C_{\\text{ss,avg}} = 1.1 \\, \\text{mg/L} $$\nNow, we can solve the steady-state mass balance equation for the dose $D$:\n$$ D = \\frac{CL \\times C_{\\text{ss,avg}} \\times \\tau}{F} $$\nThe problem provides the following values:\n- Systemic clearance, $CL = 7.2$ L/h\n- Dosing interval, $\\tau = 12$ h\n- Target average concentration, $C_{\\text{ss,avg}} = 1.1$ mg/L\n- Nominal oral bioavailability, $F = 0.42$\n\nSubstituting these values into the equation for the dose:\n$$ D = \\frac{(7.2 \\, \\text{L/h}) \\times (1.1 \\, \\text{mg/L}) \\times (12 \\, \\text{h})}{0.42} $$\nThe units are consistent: $\\frac{(\\text{L/h}) \\times (\\text{mg/L}) \\times \\text{h}}{\\text{dimensionless}} = \\text{mg}$.\n$$ D = \\frac{95.04 \\, \\text{mg}}{0.42} $$\n$$ D = 226.285714... \\, \\text{mg} $$\nRounding to four significant figures as requested, the required dose is $226.3$ mg.\n\nRegarding the sensitivity of the required dose to the uncertainty in oral bioavailability ($F$), the dose equation $D = \\frac{CL \\times C_{\\text{ss,avg}} \\times \\tau}{F}$ shows that $D$ is inversely proportional to $F$. This inverse relationship is a critical consideration in first-in-human (FIH) planning. The plausible range for $F$ is given as $0.30$ to $0.60$. This uncertainty in $F$ translates directly into a wide range of possible doses required to achieve the therapeutic target. For instance:\n- If $F = 0.30$ (worst-case absorption): $D = \\frac{95.04}{0.30} = 316.8$ mg.\n- If $F = 0.60$ (best-case absorption): $D = \\frac{95.04}{0.60} = 158.4$ mg.\nThe dose required to meet the target concentration could be nearly $40\\%$ higher or $30\\%$ lower than the dose calculated with the nominal $F$. This highlights a significant risk: if the true $F$ is higher than the nominal value of $0.42$, administering the calculated dose of $226.3$ mg could lead to unexpectedly high and potentially toxic concentrations. Conversely, if the true $F$ is lower, the dose may be sub-therapeutic.\n\nTo quantify the fractional change in the required dose if the true $F$ is $0.30$ instead of the nominal $0.42$, we can calculate the ratio. Let $D_{nominal}$ be the dose for $F_{nominal} = 0.42$ and $D_{new}$ be the dose for $F_{new} = 0.30$.\n$$ \\text{Fractional Change} = \\frac{D_{new} - D_{nominal}}{D_{nominal}} $$\nSince $D$ is proportional to $1/F$, this simplifies to:\n$$ \\text{Fractional Change} = \\frac{\\frac{k}{F_{new}} - \\frac{k}{F_{nominal}}}{\\frac{k}{F_{nominal}}} = \\frac{F_{nominal}}{F_{new}} - 1 $$\nwhere $k = CL \\times C_{\\text{ss,avg}} \\times \\tau$.\n$$ \\text{Fractional Change} = \\frac{0.42}{0.30} - 1 = 1.4 - 1 = 0.4 $$\nA bioavailability of $0.30$ instead of $0.42$ would require a $40\\%$ increase in the dose to achieve the same target steady-state concentration. This underscores the importance of carefully managing assumptions about bioavailability in early clinical development.", "answer": "$$\\boxed{226.3}$$", "id": "4598103"}, {"introduction": "Once a drug enters clinical study, a standard dose must often be adapted for special populations, such as those with organ impairment, which is a core responsibility of the clinical pharmacologist. This problem ([@problem_id:4598078]) focuses on the common challenge of adjusting a dose for a patient with reduced kidney function. You will derive and apply a dose-adjustment formula based on the principle that renal clearance scales with glomerular filtration rate, while also critically evaluating the assumptions underlying this widely used method.", "problem": "A sponsor is preparing first-in-patient dosing for an orally administered, largely renally eliminated small-molecule discovered to undergo both glomerular filtration and active secretion via Organic Anion Transporter 3 (OAT3). In a healthy reference cohort, population pharmacokinetics estimated the following at steady state under linear conditions:\n- Reference estimated Glomerular Filtration Rate (eGFR): $eGFR_{\\mathrm{ref}} = 100\\,\\mathrm{mL\\,min^{-1}\\,1.73\\,m^{-2}}$.\n- Total systemic clearance: $CL_{\\mathrm{ref}} = 12\\,\\mathrm{L\\,h^{-1}}$.\n- Renal fraction of total clearance (from a mass balance and intravenous microdose study): $f_{\\mathrm{R}} = 0.70$, so $CL_{\\mathrm{R,ref}} = f_{\\mathrm{R}}\\cdot CL_{\\mathrm{ref}}$ and $CL_{\\mathrm{NR}} = (1-f_{\\mathrm{R}})\\cdot CL_{\\mathrm{ref}}$.\n- Plasma unbound fraction: $f_{\\mathrm{u}} = 0.10$.\n- Absolute bioavailability: $F = 0.50$.\n- Reference maintenance regimen: dose $D_{\\mathrm{ref}} = 300\\,\\mathrm{mg}$ every $\\tau = 12\\,\\mathrm{h}$.\n\nA target patient has reduced renal function with $eGFR_{\\mathrm{new}} = 25\\,\\mathrm{mL\\,min^{-1}\\,1.73\\,m^{-2}}$, while nonrenal elimination pathways, plasma protein binding, and transporter expression per nephron are assumed unchanged relative to the reference cohort. Preclinical transporter kinetics for OAT3-mediated active secretion are well described by Michaelisâ€“Menten with an unbound Michaelis constant $K_{\\mathrm{m}} = 0.50\\,\\mathrm{mg\\,L^{-1}}$ and a capacity $V_{\\max}$ sufficiently large that first-order behavior holds when unbound concentrations are well below $K_{\\mathrm{m}}$.\n\nUsing only fundamental pharmacokinetic definitions and mass-balance principles for steady state under linear kinetics, proceed as follows:\n1) Starting from the relationship between average steady-state concentration, input rate, and clearance, derive a general expression for the maintenance dose $D_{\\mathrm{new}}$ (per interval $\\tau$) required to maintain the same average steady-state concentration in the target patient, when total clearance consists of a nonrenal component $CL_{\\mathrm{NR}}$ that remains unchanged and a renal component that scales in direct proportion to $eGFR$ under non-saturating conditions. Your derivation should make clear how $CL_{\\mathrm{new}}$ depends on $CL_{\\mathrm{R,ref}}$, $CL_{\\mathrm{NR}}$, $eGFR_{\\mathrm{new}}$, and $eGFR_{\\mathrm{ref}}$.\n2) Compute the numerical value of $D_{\\mathrm{new}}$ for the target patient, rounding your final dose to three significant figures and expressing it in $\\mathrm{mg}$. Assume the goal is to match the reference average steady-state concentration.\n3) Using the provided $K_{\\mathrm{m}}$ and the reference regimen, assess whether the assumption of proportional renal clearance to $eGFR$ is valid in this case by comparing the reference unbound average steady-state concentration to $K_{\\mathrm{m}}$. Discuss under what conditions transporter saturation would invalidate proportionality, even if $eGFR$ changes proportionally.\n\nRound your final numerical dose to three significant figures. Express the final dose in $\\mathrm{mg}$.", "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It is based on established principles of clinical pharmacokinetics and presents a realistic clinical scenario for dose adjustment in renal impairment. The data provided are self-contained, consistent, and sufficient to derive the required expressions, perform the calculations, and critically evaluate the underlying assumptions. The problem is therefore deemed valid.\n\nThe solution will be presented in three parts as requested.\n\n### Part 1: Derivation of the General Expression for Maintenance Dose\n\nThe average steady-state plasma concentration, $C_{\\mathrm{ss,avg}}$, is defined as the state where the rate of drug administration into the systemic circulation equals the rate of drug elimination from the systemic circulation.\n\nFor an orally administered drug with bioavailability $F$, given at a maintenance dose $D$ every dosing interval $\\tau$, the average rate of drug input is $\\frac{F \\cdot D}{\\tau}$.\nThe average rate of elimination is the product of the total systemic clearance $CL$ and the average steady-state concentration $C_{\\mathrm{ss,avg}}$.\nEquating these rates gives the fundamental relationship:\n$$C_{\\mathrm{ss,avg}} \\cdot CL = \\frac{F \\cdot D}{\\tau}$$\nThis can be rearranged to express the average steady-state concentration:\n$$C_{\\mathrm{ss,avg}} = \\frac{F \\cdot D}{CL \\cdot \\tau}$$\nThe objective is to find a new maintenance dose, $D_{\\mathrm{new}}$, for a target patient (new) that achieves the same average steady-state concentration as a reference regimen ($D_{\\mathrm{ref}}, \\tau, CL_{\\mathrm{ref}}$) in a healthy cohort (ref). Therefore, we set $C_{\\mathrm{ss,avg,new}} = C_{\\mathrm{ss,avg,ref}}$.\n$$\\frac{F \\cdot D_{\\mathrm{new}}}{CL_{\\mathrm{new}} \\cdot \\tau} = \\frac{F \\cdot D_{\\mathrm{ref}}}{CL_{\\mathrm{ref}} \\cdot \\tau}$$\nThe problem assumes that the bioavailability $F$ and the dosing interval $\\tau$ remain unchanged between the reference and target patient. Thus, these terms cancel out, yielding the general dose-adjustment principle:\n$$\\frac{D_{\\mathrm{new}}}{CL_{\\mathrm{new}}} = \\frac{D_{\\mathrm{ref}}}{CL_{\\mathrm{ref}}}$$\n$$D_{\\mathrm{new}} = D_{\\mathrm{ref}} \\cdot \\frac{CL_{\\mathrm{new}}}{CL_{\\mathrm{ref}}}$$\nThe next step is to derive an expression for the new total clearance, $CL_{\\mathrm{new}}$. Total clearance is the sum of its renal ($CL_{\\mathrm{R}}$) and nonrenal ($CL_{\\mathrm{NR}}$) components:\n$$CL_{\\mathrm{new}} = CL_{\\mathrm{R,new}} + CL_{\\mathrm{NR,new}}$$\nThe problem states that nonrenal clearance is unchanged, so $CL_{\\mathrm{NR,new}} = CL_{\\mathrm{NR,ref}}$. It also states that renal clearance scales in direct proportion to the estimated Glomerular Filtration Rate ($eGFR$) under non-saturating conditions. This means:\n$$\\frac{CL_{\\mathrm{R,new}}}{CL_{\\mathrm{R,ref}}} = \\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}}$$\nThus, the new renal clearance is:\n$$CL_{\\mathrm{R,new}} = CL_{\\mathrm{R,ref}} \\cdot \\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}}$$\nSubstituting these components into the expression for $CL_{\\mathrm{new}}$:\n$$CL_{\\mathrm{new}} = \\left( CL_{\\mathrm{R,ref}} \\cdot \\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}} \\right) + CL_{\\mathrm{NR,ref}}$$\nFinally, substituting this expression for $CL_{\\mathrm{new}}$ into the dose adjustment formula provides the required general expression for $D_{\\mathrm{new}}$:\n$$D_{\\mathrm{new}} = D_{\\mathrm{ref}} \\cdot \\frac{CL_{\\mathrm{R,ref}} \\cdot \\left(\\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}}\\right) + CL_{\\mathrm{NR,ref}}}{CL_{\\mathrm{ref}}}$$\nGiven that $CL_{\\mathrm{ref}} = CL_{\\mathrm{R,ref}} + CL_{\\mathrm{NR,ref}}$, the expression can also be written as:\n$$D_{\\mathrm{new}} = D_{\\mathrm{ref}} \\cdot \\frac{CL_{\\mathrm{R,ref}} \\cdot \\left(\\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}}\\right) + CL_{\\mathrm{NR,ref}}}{CL_{\\mathrm{R,ref}} + CL_{\\mathrm{NR,ref}}}$$\nThis expression clearly shows how the new dose depends on the reference dose, the components of reference clearance, and the ratio of the new to reference $eGFR$.\n\n### Part 2: Computation of the New Maintenance Dose\n\nFirst, we calculate the numerical values for the components of the reference clearance.\nGiven:\n$CL_{\\mathrm{ref}} = 12\\,\\mathrm{L\\,h^{-1}}$\n$f_{\\mathrm{R}} = 0.70$\nReference renal clearance, $CL_{\\mathrm{R,ref}}$:\n$$CL_{\\mathrm{R,ref}} = f_{\\mathrm{R}} \\cdot CL_{\\mathrm{ref}} = 0.70 \\cdot 12\\,\\mathrm{L\\,h^{-1}} = 8.4\\,\\mathrm{L\\,h^{-1}}$$\nReference nonrenal clearance, $CL_{\\mathrm{NR,ref}}$:\n$$CL_{\\mathrm{NR,ref}} = (1 - f_{\\mathrm{R}}) \\cdot CL_{\\mathrm{ref}} = (1 - 0.70) \\cdot 12\\,\\mathrm{L\\,h^{-1}} = 0.30 \\cdot 12\\,\\mathrm{L\\,h^{-1}} = 3.6\\,\\mathrm{L\\,h^{-1}}$$\nNext, we calculate the new total clearance, $CL_{\\mathrm{new}}$, for the target patient.\nGiven:\n$eGFR_{\\mathrm{ref}} = 100\\,\\mathrm{mL\\,min^{-1}\\,1.73\\,m^{-2}}$\n$eGFR_{\\mathrm{new}} = 25\\,\\mathrm{mL\\,min^{-1}\\,1.73\\,m^{-2}}$\nThe scaling factor for renal clearance is:\n$$\\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}} = \\frac{25}{100} = 0.25$$\nThe new renal clearance is:\n$$CL_{\\mathrm{R,new}} = CL_{\\mathrm{R,ref}} \\cdot \\frac{eGFR_{\\mathrm{new}}}{eGFR_{\\mathrm{ref}}} = 8.4\\,\\mathrm{L\\,h^{-1}} \\cdot 0.25 = 2.1\\,\\mathrm{L\\,h^{-1}}$$\nThe new total clearance is the sum of the new renal clearance and the unchanged nonrenal clearance:\n$$CL_{\\mathrm{new}} = CL_{\\mathrm{R,new}} + CL_{\\mathrm{NR,ref}} = 2.1\\,\\mathrm{L\\,h^{-1}} + 3.6\\,\\mathrm{L\\,h^{-1}} = 5.7\\,\\mathrm{L\\,h^{-1}}$$\nNow, we can compute the new maintenance dose, $D_{\\mathrm{new}}$, using the reference dose $D_{\\mathrm{ref}} = 300\\,\\mathrm{mg}$:\n$$D_{\\mathrm{new}} = D_{\\mathrm{ref}} \\cdot \\frac{CL_{\\mathrm{new}}}{CL_{\\mathrm{ref}}} = 300\\,\\mathrm{mg} \\cdot \\frac{5.7\\,\\mathrm{L\\,h^{-1}}}{12\\,\\mathrm{L\\,h^{-1}}}$$\n$$D_{\\mathrm{new}} = 300\\,\\mathrm{mg} \\cdot 0.475 = 142.5\\,\\mathrm{mg}$$\nThe problem requires the final dose to be rounded to three significant figures.\n$$D_{\\mathrm{new}} \\approx 143\\,\\mathrm{mg}$$\n\n### Part 3: Assessment of the Proportionality Assumption\n\nThe assumption that renal clearance ($CL_{\\mathrm{R}}$) is proportional to $eGFR$ is valid only if the mechanisms of renal elimination (glomerular filtration and active tubular secretion) behave as first-order processes. Active transport, governed by Michaelis-Menten kinetics, approximates a first-order process when the unbound substrate concentration ($C_{\\mathrm{u}}$) is substantially lower than the Michaelis constant ($K_{\\mathrm{m}}$).\n\nFirst, let's assess this condition for the reference cohort by calculating the average unbound steady-state concentration, $C_{\\mathrm{ss,avg,u,ref}}$.\nThe total average steady-state concentration is:\n$$C_{\\mathrm{ss,avg,ref}} = \\frac{F \\cdot D_{\\mathrm{ref}}}{CL_{\\mathrm{ref}} \\cdot \\tau} = \\frac{0.50 \\cdot 300\\,\\mathrm{mg}}{12\\,\\mathrm{L\\,h^{-1}} \\cdot 12\\,\\mathrm{h}} = \\frac{150\\,\\mathrm{mg}}{144\\,\\mathrm{L}} \\approx 1.0417\\,\\mathrm{mg\\,L^{-1}}$$\nThe unbound concentration is this value multiplied by the unbound fraction, $f_{\\mathrm{u}} = 0.10$:\n$$C_{\\mathrm{ss,avg,u,ref}} = C_{\\mathrm{ss,avg,ref}} \\cdot f_{\\mathrm{u}} \\approx 1.0417\\,\\mathrm{mg\\,L^{-1}} \\cdot 0.10 \\approx 0.104\\,\\mathrm{mg\\,L^{-1}}$$\nWe compare this to the given Michaelis constant, $K_{\\mathrm{m}} = 0.50\\,\\mathrm{mg\\,L^{-1}}$.\nThe ratio is:\n$$\\frac{C_{\\mathrm{ss,avg,u,ref}}}{K_{\\mathrm{m}}} \\approx \\frac{0.104\\,\\mathrm{mg\\,L^{-1}}}{0.50\\,\\mathrm{mg\\,L^{-1}}} \\approx 0.21$$\nThe average unbound concentration is approximately $21\\%$ of the $K_{\\mathrm{m}}$. While not negligible, this value may be considered low enough for the first-order approximation to be reasonably acceptable, though it indicates that some degree of saturation is occurring. The rate of a Michaelis-Menten process at $C_u = 0.21 K_m$ is $V_{max} \\frac{0.21 K_m}{K_m + 0.21 K_m} \\approx 0.17 V_{max}$, whereas a purely linear process would have a rate proportional to $0.21$. This represents a deviation of about $1 - (0.17/0.21) \\approx 19\\%$ from perfect linearity for the secretion component.\n\nTransporter saturation would more definitively invalidate the proportionality assumption under conditions where the distinct components of renal clearance do not scale uniformly with a change in $eGFR$.\nRenal clearance is the sum of filtration clearance and net secretion clearance: $CL_{\\mathrm{R}} = CL_{\\mathrm{filt}} + CL_{\\mathrm{sec}}$.\n$CL_{\\mathrm{filt}} = f_{\\mathrm{u}} \\cdot GFR$. This component is always linear and scales directly with $GFR$.\nThe clearance for active secretion, however, is concentration-dependent: $CL_{\\mathrm{sec}} = \\frac{\\text{Rate of secretion}}{C} = \\frac{V_{\\mathrm{max}} \\cdot f_{\\mathrm{u}}}{K_{\\mathrm{m}} + f_{\\mathrm{u}} \\cdot C}$.\nThe simple proportionality model, $CL_{\\mathrm{R}} \\propto eGFR$, implicitly assumes that $CL_{\\mathrm{filt}}$ and $CL_{\\mathrm{sec}}$ both scale with $eGFR$. This holds if $C_{\\mathrm{u}} \\ll K_{\\mathrm{m}}$ (linear region) and if the secretory capacity ($V_{\\mathrm{max}}$) is itself proportional to $eGFR$, which is a plausible biological assumption as both may reflect the number of functioning nephrons.\n\nThe proportionality assumption is invalidated by saturation under two key conditions:\n$1$. The concentration $C_{\\mathrm{u}}$ is a significant fraction of $K_{\\mathrm{m}}$, causing $CL_{\\mathrm{sec}}$ to be nonlinear.\n$2$. The pathological process of renal impairment disproportionately affects different parts of the nephron. The assumption that secretory capacity ($V_{\\mathrm{max}}$) declines in direct proportion to $GFR$ may not hold. For example, a tubulointerstitial disease might damage transporters and reduce $V_{\\mathrm{max}}$ more significantly than the decline in $GFR$. In this scenario, the total $CL_{\\mathrm{R}}$ would decrease more than predicted by the fall in $eGFR$ alone. Conversely, a primary glomerular disease might reduce $GFR$ with less impact on secretory capacity, causing $CL_{\\mathrm{R}}$ to decrease less than predicted. When concentrations are high enough to cause saturation, the system is nonlinear, and the overall clearance becomes much more sensitive to which component ($GFR$ or $V_{\\mathrm{max}}$) is more severely affected, thus breaking the simple proportionality to $eGFR$. In this specific problem, secretion is the dominant renal pathway (approximately $130\\,\\mathrm{mL\\,min^{-1}}$ of secretion vs. $10\\,\\mathrm{mL\\,min^{-1}}$ of filtration), so any deviation from proportional scaling of secretion would have a large impact on the total renal clearance.", "answer": "$$ \\boxed{143} $$", "id": "4598078"}, {"introduction": "As a drug progresses towards late-stage development, the final task is to select the best dose for the market, a decision that demands a formal balancing of efficacy and safety across a population. This practice ([@problem_id:4598068]) introduces a decision-analytic utility function that quantitatively combines models for a drug's therapeutic benefit and its toxicity risk. By optimizing this function, you will see how pharmacometric analysis provides a rational basis for making high-stakes dose selection decisions for Phase III trials.", "problem": "A Phase II program for a novel oral small molecule has completed dose-ranging studies, yielding a posterior distribution over efficacy and safety parameters that will inform Phase III dose selection. The pharmacodynamic model for efficacy is assumed to follow a saturating maximum-effect form: the expected change from baseline in a continuous clinical response (for example, symptom score reduction) at dose $d$ is given by $E(d) = E_{\\max} \\times \\frac{d}{EC_{50} + d}$, where $E_{\\max}$ denotes the maximum achievable effect and $EC_{50}$ denotes the dose at which one-half of $E_{\\max}$ is achieved. The posterior mean estimates are $E_{\\max} = 2.5$ (in response units) and $EC_{50} = 60$ milligrams. Safety is summarized for the purpose of decision-making as the probability of a dose-limiting toxicity (DLT) within a fixed assessment window. For the dose range considered in Phase II ($d \\in [0,120]$ milligrams), the posterior mean safety model can be approximated as linear: $\\Pr(\\text{DLT} \\mid d) \\approx \\eta d$, with posterior mean $\\eta = 5.0 \\times 10^{-4}$ per milligram.\n\nDefine a decision-analytic utility function $U(d)$ as the weighted benefit minus weighted risk, $U(d) = w_{e} \\,\\mathbb{E}[E(d)] - w_{s} \\, C_{\\text{tox}} \\,\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$, where $w_{e}$ and $w_{s}$ are dimensionless weights reflecting the relative importance of efficacy and safety in the targeted indication, and $C_{\\text{tox}}$ is a dimensioned scalar translating toxicity probability into the same utility scale as efficacy. For this program, set $w_{e} = 1$, $w_{s} = 1$, and $C_{\\text{tox}} = 30$ utility units per unit probability. Assume the posterior mean models above represent $\\mathbb{E}[E(d)]$ and $\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$ in this dose range.\n\nStarting from first principles of model-based decision analysis and without invoking any shortcut formulas, derive the dose $d^{\\ast}$ that maximizes $U(d)$ over the feasible range $d \\in [0,120]$ milligrams. Express your final result for $d^{\\ast}$ in milligrams and round your answer to three significant figures.", "solution": "The problem requires finding the optimal dose $d^{\\ast}$ that maximizes a decision-analytic utility function $U(d)$ over a specified dose range. The problem is well-posed and scientifically grounded in the principles of pharmacometric modeling and decision analysis.\n\nThe utility function is defined as a weighted difference between the expected efficacy (benefit) and the expected safety (risk):\n$$U(d) = w_{e} \\,\\mathbb{E}[E(d)] - w_{s} \\, C_{\\text{tox}} \\,\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$$\n\nThe expected efficacy, $\\mathbb{E}[E(d)]$, is given by a saturating maximum-effect ($E_{\\max}$) model, using the posterior mean estimates for the parameters:\n$$\\mathbb{E}[E(d)] = E_{\\max} \\times \\frac{d}{EC_{50} + d}$$\n\nThe expected probability of a dose-limiting toxicity (DLT), $\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$, is approximated by a linear model using its posterior mean parameter:\n$$\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)] = \\eta d$$\n\nSubstituting these models into the utility function gives:\n$$U(d) = w_{e} E_{\\max} \\frac{d}{EC_{50} + d} - w_{s} C_{\\text{tox}} \\eta d$$\n\nThe given values for the parameters are:\n- Efficacy weight $w_{e} = 1$\n- Safety weight $w_{s} = 1$\n- Maximum effect $E_{\\max} = 2.5$ response units\n- Half-maximal effective dose $EC_{50} = 60$ milligrams\n- Toxicity cost $C_{\\text{tox}} = 30$ utility units per unit probability\n- Toxicity slope $\\eta = 5.0 \\times 10^{-4}$ per milligram\n\nSubstituting these numerical values into the expression for $U(d)$:\n$$U(d) = (1)(2.5) \\frac{d}{60 + d} - (1)(30)(5.0 \\times 10^{-4})d$$\n$$U(d) = \\frac{2.5d}{d+60} - (150 \\times 10^{-4})d$$\n$$U(d) = \\frac{2.5d}{d+60} - 0.015d$$\n\nTo find the dose $d^{\\ast}$ that maximizes $U(d)$, we must find the critical points by taking the first derivative of $U(d)$ with respect to $d$ and setting it to zero. The optimization is performed over the feasible range $d \\in [0, 120]$ milligrams.\n\nFirst, we compute the derivative $\\frac{dU}{dd}$:\n$$\\frac{dU}{dd} = \\frac{d}{dd} \\left( \\frac{2.5d}{d+60} - 0.015d \\right)$$\nUsing the quotient rule for the first term, $\\frac{d}{dx}\\left(\\frac{u}{v}\\right) = \\frac{u'v - uv'}{v^2}$, where $u=2.5d$ and $v=d+60$:\n$$\\frac{d}{dd}\\left( \\frac{2.5d}{d+60} \\right) = \\frac{(2.5)(d+60) - (2.5d)(1)}{(d+60)^2} = \\frac{2.5d + 150 - 2.5d}{(d+60)^2} = \\frac{150}{(d+60)^2}$$\nThe derivative of the second term is:\n$$\\frac{d}{dd}(-0.015d) = -0.015$$\nCombining the terms, we get the full derivative:\n$$\\frac{dU}{dd} = \\frac{150}{(d+60)^2} - 0.015$$\n\nTo find the critical points, we set the derivative equal to zero:\n$$\\frac{150}{(d+60)^2} - 0.015 = 0$$\n$$\\frac{150}{(d+60)^2} = 0.015$$\n$$(d+60)^2 = \\frac{150}{0.015} = \\frac{150}{15/1000} = \\frac{150 \\times 1000}{15} = 10 \\times 1000 = 10000$$\nTaking the square root of both sides:\n$$d+60 = \\pm\\sqrt{10000} = \\pm 100$$\nThis yields two possible values for $d$:\n$1$. $d + 60 = 100 \\implies d = 100 - 60 = 40$\n$2$. $d + 60 = -100 \\implies d = -100 - 60 = -160$\n\nSince the dose $d$ must be a non-negative quantity, the solution $d = -160$ is not physically meaningful and is discarded. The only valid critical point is $d = 40$.\n\nTo confirm that this critical point corresponds to a maximum, we use the second derivative test. We compute the second derivative $\\frac{d^2U}{dd^2}$:\n$$\\frac{d^2U}{dd^2} = \\frac{d}{dd} \\left( \\frac{150}{(d+60)^2} - 0.015 \\right) = \\frac{d}{dd} \\left( 150(d+60)^{-2} \\right)$$\n$$\\frac{d^2U}{dd^2} = 150 \\times (-2)(d+60)^{-3} = \\frac{-300}{(d+60)^3}$$\nFor any non-negative dose $d \\ge 0$, the term $(d+60)^3$ is positive. Therefore, $\\frac{d^2U}{dd^2}$ is always negative for $d \\ge 0$. This indicates that the utility function $U(d)$ is strictly concave for all physically relevant doses, and the critical point $d = 40$ corresponds to a unique global maximum.\n\nFinally, we must check if this optimal dose lies within the feasible dose range specified in the problem, which is $d \\in [0, 120]$ milligrams. The calculated optimal dose $d^{\\ast} = 40$ is indeed within this interval. Because the function is concave and the unconstrained maximum is within the interval, it is also the maximum over that interval.\n\nThe question asks for the result to be rounded to three significant figures. The optimal dose is exactly $40$ milligrams, which is written as $40.0$ to show three significant figures of precision.", "answer": "$$\\boxed{40.0}$$", "id": "4598068"}]}